Inmune Bio grants director 100,000 stock options

Inmune Bio director James Sapirstein received 100,000 time-vested stock options as board compensation, exercisable at $2.33 per share through 2036.

Rhea-AI Filing Summary

Inmune Bio, Inc. (INMB) reported that director James Sapirstein received a grant of 100,000 stock options on September 15, 2026 as compensation for his service on the board of directors. The options have an exercise price of $2.33 per share and are exercisable for 100,000 shares of common stock.

The award was granted under Inmune Bio, Inc.'s Third Amended and Restated 2021 Stock Incentive Plan and vests in 36 equal monthly installments over three years, beginning one month after the grant date, becoming fully vested on the third anniversary of the grant. Following this award, Sapirstein holds stock options for 100,000 shares, with the options scheduled to expire on September 14, 2036. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider SAPIRSTEIN JAMES

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 100,000 contracts (Direct)

Footnotes (1)

1. F1. Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant.

Key Figures

Stock options granted: 100,000 options Exercise price: $2.33 per share Underlying common shares: 100,000 shares +2 more

5 metrics

Stock options granted 100,000 options Initial award to director James Sapirstein on September 15, 2026

Exercise price $2.33 per share Exercise price of options granted September 15, 2026

Underlying common shares 100,000 shares Shares of Inmune Bio, Inc. common stock underlying the options

Vesting schedule 36 equal monthly installments over 3 years Vesting begins one month after grant and ends on third anniversary

Option expiration date September 14, 2036 Scheduled expiration of the granted stock options

Key Terms

Stock Incentive Plan, vest, exercise price

3 terms

Stock Incentive Plan financial

"Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan."

A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.

vest financial

"The options will vest in 36 equal installments over three (3) years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"The options have an exercise price of $2.33 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity compensation did INMB director James Sapirstein receive?

James Sapirstein received a grant of 100,000 stock options on September 15, 2026 as an initial award for his service on the board of directors of Inmune Bio, Inc., under the company’s Third Amended and Restated 2021 Stock Incentive Plan.

What is the exercise price of James Sapirstein’s new INMB stock options?

The stock options granted to James Sapirstein have an exercise price of $2.33 per share. Each option is exercisable for one share of Inmune Bio, Inc. common stock, subject to the vesting schedule described in the award terms.

How do the INMB stock options granted to James Sapirstein vest?

The options vest in 36 equal installments over three years, with one thirty-sixth of the award vesting each month. Vesting begins one month after the September 15, 2026 grant date, and the options will be 100% vested on the third anniversary of the grant.

When do James Sapirstein’s INMB stock options expire?

The options granted to James Sapirstein are scheduled to expire on September 14, 2036. After that date, any unexercised options will no longer be exercisable for shares of Inmune Bio, Inc. common stock.

How many INMB shares are underlying James Sapirstein’s new stock options?

The grant covers 100,000 shares of Inmune Bio, Inc. common stock. Each option corresponds to one underlying share, so if fully vested and exercised, the options could be converted into 100,000 shares of common stock.

Were James Sapirstein’s INMB option grants made under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this transaction. The options are described as an initial award for his service on the board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 01:44 PM Accepted by SEC EDGAR 09/17/2026 - 01:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAPIRSTEIN JAMES

(Last) (First) (Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$2.33	09/15/2026		A		100,000		(1)	09/14/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant.

	/s/ James Sapirstein	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)